IBEX 35
11.327,70 +28,40 (+0,25%) Euro Stoxx 50
5.064,14 -8,31 (-0,16%) Dólar/Euro
1,0873 +0,0004 (+0,03%) Petróleo Brent
83,94 +0,67 (+0,80%) Oro
2.423,20 +37,70 (+1,58%) Bitcoin EUR
61.493,30 +1.468,21 (+2,45%)
Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd.
Jerusalem BioPark Building
2nd floor Hadassah Ein Kerem Campus
Jerusalem
Israel
972 8 930 2529
https://www.scinai.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director | 562k | N/A | 1976 |
| Mr. Joshua E. Phillipson B.Sc., M.B.A. | Director of Communications & Investor Relations | N/A | N/A | N/A |
| Liat Halpert | Head of Business Development & Sales | N/A | N/A | N/A |
| Merav Kamensky | Head of Quality Control | N/A | N/A | N/A |
Descripción
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Gobierno corporativo
El ISS Governance QualityScore de Scinai Immunotherapeutics Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
